Study to Evaluate the Safety and Effects AZD0530 on Prostate and Breast Cancer Subjects With Metastatic Bone Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

139

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

January 31, 2010

Study Completion Date

August 31, 2012

Conditions
Breast CancerProstate CancerBone Neoplasms
Interventions
DRUG

AZD0530

Daily oral dose

DRUG

Zoledronic Acid

Trial Locations (28)

Unknown

Research Site, Pleasant Hill

Research Site, Sacramento

Research Site, Middlebury

Research Site, Aventura

Research Site, Baltimore

Research Site, Ann Arbor

Research Site, Poughkeepsie

Research Site, Winston-Salem

Research Site, Hershey

Research Site, Edmonton

Research Site, Vancouver

Research Site, Toronto

Research Site, Montreal

Research Site, Québec

Research Site, Arhus N

Research Site, Frederica

Research Site, Herlev

Research Site, Holstebro

Research Site, Kristiansand

Research Site, Oslo

Research Site, Lisbon

Research Site, Barcelona

Research Site, Lleida

Research Site, Valencia

Research Site, Uppsala

Research Site, Cardiff

Research Site, Glasgow

Research Site, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY